Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 8, 836 (1 November 2009) | doi:10.1038/nrd3039
Trial watch: CGRP receptor antagonist meets Phase III migraine end points
Abstract
Merck has announced that the antagonist of the calcitonin gene-related peptide (CGRP) receptor telcagepant has met the primary end points in two Phase III trials to treat migraine, which is characterized by attacks of intense throbbing head pain that can last from 4 to 72 hours. One study showed that the compound led to significant pain relief compared with placebo 2 hours after treatment and sustained freedom from pain up to 24 hours after treatment.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
